Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Category: Diabetes

1336-OR: A Lactate-PFKL Lactylation Positive Circuit Promotes the Progression of MASLD

June 9, 2026 by sugaradmin

Introduction and Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health challenge with limited effective pharmacological therapies. Although lysine lactylation has emerged as an important regulator of metabolic homeostasis, whether lactylation of the key glycolytic enzyme phosphofructokinase liver type (PFKL) drives MASLD progression and the underlying mechanisms remain obscure.Methods: Quantitative lactylome and […]

Read More
DiabetesLeave a Comment on 1336-OR: A Lactate-PFKL Lactylation Positive Circuit Promotes the Progression of MASLD

1292-OR: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonist Use among Adults with Type 1 Diabetes and Overweight or Obesity: A Target Trial Emulation Using Real-World EHR Data

June 9, 2026 by sugaradmin

Introduction and Objective: Evidence for GLP-1RA-associated cardiovascular benefits in type 1 diabetes (T1D) remains scarce. Using a target trial emulation, we assessed the impact of GLP-1RA use on cardiovascular outcomes in a high-risk cohort of adults with T1D and overweight or obesity.Methods: We emulated a target trial using electronic health records from Epic COSMOS database. […]

Read More
DiabetesLeave a Comment on 1292-OR: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonist Use among Adults with Type 1 Diabetes and Overweight or Obesity: A Target Trial Emulation Using Real-World EHR Data

1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation

June 9, 2026 by sugaradmin

Introduction and Objective: MASLD is a common polygenic condition, but current GWASs have only identified 14 loci due to a lack of scalable, clinically relevant phenotypes.Methods: Using machine learning on four UKBB data modalities (MRI, DXA, plasma metabolites, blood biomarkers; n=25,474 to 262,927), we predicted liver fat (LF) and adipose tissue volume (ATV), increasing statistical […]

Read More
DiabetesLeave a Comment on 1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation

1302-OR: Diabetes Nurse Practitioner–Led Management in Transitional Care Center Reduced 90-Day Utilization and Costs in High-Risk Patients

June 9, 2026 by sugaradmin

Introduction and Objective: The organization’s transitional care center (TCC) has reduced overall rehospitalizations. Initiative evaluated whether DM nurse practitioner (NP) led post-discharge management in TCC, coupled with CHW support with SDOH barriers, reduces 90-day healthcare utilization and costs among people hospitalized with diabetes, compared to 90 days prior to index admission.Methods: In 2025, DM NP […]

Read More
DiabetesLeave a Comment on 1302-OR: Diabetes Nurse Practitioner–Led Management in Transitional Care Center Reduced 90-Day Utilization and Costs in High-Risk Patients

1325-OR: Deficient β-Cell Reserve and Exocrine Insufficiency Synergistically Drive Glycemic Variability in Chronic Pancreatitis

June 9, 2026 by sugaradmin

Introduction and Objective: Post-pancreatitis diabetes mellitus (PPDM-C) is characterized by dual exocrine and endocrine failure. However, the impact of exocrine insufficiency (PEI) on β-cell reserve and glycemic variability remains underdefined. This study aims to elucidate the characteristics of islet function in CP and the influence of exocrine status on glucose homeostasis.Methods: We analyzed 148 CP […]

Read More
DiabetesLeave a Comment on 1325-OR: Deficient β-Cell Reserve and Exocrine Insufficiency Synergistically Drive Glycemic Variability in Chronic Pancreatitis

1288-OR: Stakeholder-Guided Design of a Pediatric Type 2 Diabetes Group Education Curriculum

June 9, 2026 by sugaradmin

Introduction and Objective: Effective care models are needed for youth with type 2 diabetes (YT2D). Shared medical appointments using group education modules benefitted youth with T1D. This study aimed to design group education modules called Team Clinic for T2D (TCT2) with input from primarily Latinx, publicly insured YT2D, caregivers, and clinicians.Methods: An iterative human-centered design […]

Read More
DiabetesLeave a Comment on 1288-OR: Stakeholder-Guided Design of a Pediatric Type 2 Diabetes Group Education Curriculum

1299-OR: Concordance of Libre, Dexcom, and Medtronic Glucose Management Indicator (GMI) and Laboratory HbA1c

June 9, 2026 by sugaradmin

Introduction and Objective: A recent study comparing Freestyle Libre (FSL) 3, Dexcom (Dex) G7, and Medtronic (Med) Simplera CGM systems found discordant glycaemic metrics, with Med showing a significantly lower glucose management indicator (GMI) and a higher time-in-range. The purpose of this study was to assess concordance between laboratory HbA1c and GMI from three sensor […]

Read More
DiabetesLeave a Comment on 1299-OR: Concordance of Libre, Dexcom, and Medtronic Glucose Management Indicator (GMI) and Laboratory HbA1c

1280-OR: Association between Preprocedural Glycemia and Adverse Cardiovascular Outcomes following Endovascular Revascularization in Diabetic Patients with Lower Extremity Arteriosclerosis Obliterans

June 9, 2026 by sugaradmin

Introduction and Objective: The association between preprocedural glycemia and major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs) after endovascular revascularization in diabetic patients with lower extremity arteriosclerosis obliterans (LEASO) remains unclear. The aim of this study is to explore the link between preprocedural glycaemic control and the 1-year risk of MACEs and […]

Read More
DiabetesLeave a Comment on 1280-OR: Association between Preprocedural Glycemia and Adverse Cardiovascular Outcomes following Endovascular Revascularization in Diabetic Patients with Lower Extremity Arteriosclerosis Obliterans

1267-OR: Ademaglitazone Improves Whole-Body Insulin Sensitivity while Limiting Adipogenesis and Promoting Neuroprotection in Diet-Induced Diabesity

June 9, 2026 by sugaradmin

Introduction and Objective: “Diabesity,” the coexistence of obesity and type 2 diabetes, is a major global health problem characterized by systemic insulin resistance (IR) and increased risk of neurodegenerative complications. Although thiazolidinedione (TZD) PPAR-γ agonists improve insulin sensitivity, their clinical use is limited by adverse effects including adipogenesis, weight gain, and cardiovascular risk. We developed […]

Read More
DiabetesLeave a Comment on 1267-OR: Ademaglitazone Improves Whole-Body Insulin Sensitivity while Limiting Adipogenesis and Promoting Neuroprotection in Diet-Induced Diabesity

1231-OR: Glucocorticoid Receptor Is Vital for Maternal β-Cell Compensation to Protect against Gestational Diabetes

June 9, 2026 by sugaradmin

Introduction and Objective: Gestational β-cell compensation is an adaptive mechanism by which maternal islets increase insulin secretion to overcome pregnancy-induced insulin resistance. Defective β-cell compensation leads to gestational diabetes mellitus (GDM). We characterized the role of glucocorticoid receptor (GR) in gestational β-cell compensation.Methods: We generated β-cell GR-knockout (βGR-KO) mice, followed by determining the abilities of […]

Read More
DiabetesLeave a Comment on 1231-OR: Glucocorticoid Receptor Is Vital for Maternal β-Cell Compensation to Protect against Gestational Diabetes

Posts navigation

Older posts
Newer posts

Recent Posts

  • Overlooked Signs You Shouldn’t Ignore
  • Many Obesity Drugs Do Not Improve Quality of Life
  • Prevalence, incidence, mortality, and years of life lost to diabetes from 1996 to 2024 in Denmark
  • Smelling Chocolate May Help Boost Workouts, Reduce Hunger
  • No Link To Prenatal Tylenol Use, Studies Confirm

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness